Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MDM2 | Q00987 | 3/20 | 0.58 |
| ▸ | MDM4 | O15151 | 3/20 | 0.54 |
| ▸ | TP53 | P04637 | 3/20 | 0.54 |
| ▸ | CASP3 | P42574 | 2/20 | 0.52 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.47 |
| ▸ | TNF | P01375 | 1/20 | 0.47 |
| ▸ | TLR2 | O60603 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL120602 | 1.00 | MDM2 (0.58) | MDM2MDM4TP53CASP3PTPN1 | |
| SCHEMBL30054917 | 1.00 | MDM2 (0.58) | MDM2MDM4TP53CASP3PTPN1 | |
| SCHEMBL29397837 | 1.00 | MDM2 (0.58) | MDM2MDM4TP53CASP3PTPN1 | |
| SCHEMBL29402291 | 1.00 | MDM2 (0.58) | MDM2MDM4TP53CASP3PTPN1 | |
| SCHEMBL3227582 | 1.00 | MDM2 (0.58) | MDM2MDM4TP53CASP3PTPN1 | |
| SCHEMBL30051460 | 1.00 | MDM2 (0.58) | MDM2MDM4TP53CASP3PTPN1 | |
| SCHEMBL118169 | 0.92 | MDM4 (0.59) | MDM2MDM4TP53CASP3TNF | |
| SCHEMBL29398498 | 0.92 | MDM4 (0.59) | MDM2MDM4TP53CASP3TNF | |
| SCHEMBL119455 | 0.92 | MDM4 (0.59) | MDM2MDM4TP53CASP3TNF | |
| SCHEMBL1228254 | 0.92 | MDM4 (0.59) | MDM2MDM4TP53CASP3TNF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9345789-B2 | Specific inhibitors and active site probes for legumain | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2016-05-24 | — | — | US | disclosed |
| US-9115169-B2 | Method of treating tumors | LYTIX BIOPHARMA AS (NO) | 2015-08-25 | — | — | US | disclosed |
| US-9109048-B2 | Inhibition of tumor growth | LYTIX BIOPHARMA AS (NO) | 2015-08-18 | — | — | US | disclosed |
| US-8895231-B2 | Patterning process and resist composition | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2014-11-25 | — | — | US | disclosed |
| US-8673904-B2 | Epoxide inhibitors of cysteine proteases | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2014-03-18 | — | — | US | disclosed |
| US-8673904-B2 | Epoxide inhibitors of cysteine proteases | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2014-03-18 | — | — | US | disclosed |
| US-20140037657-A1 | INHIBITION OF TUMOR GROWTH | LYTIX BIOPHARMA AS (NO) | 2014-02-06 | — | — | US | disclosed |
| US-8338565-B2 | Macrocyclic compounds for inhibition of tumor necrosis factor alpha | ENSEMBLE THERAPEUTICS CORPORATION (US) | 2012-12-25 | — | — | US | disclosed |
| US-8283315-B2 | Inhibition of tumour growth | LYTIX BIOPHARMA AS (NO) | 2012-10-09 | — | — | US | disclosed |
| US-20120251459-A1 | SPECIFIC INHIBITORS AND ACTIVE SITE PROBES FOR LEGUMAIN | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2012-10-04 | — | — | US | disclosed |
| US-6890902-B2 | Cytotoxic modified lactoferrin peptides | ALPHARMA AS (NO) | 2005-05-10 | — | — | US | disclosed |
| US-20030195144-A1 | Antimicrobial compounds and formulations | LYTIX BIOPHARMA AS (NO) | 2003-10-16 | — | — | US | disclosed |
| US-20030148936-A1 | Bioactive peptides | ALPHARMA AS. | 2003-08-07 | — | — | US | disclosed |
| US-20030022821-A1 | Bioactive peptides | ALPHARMA AS | 2003-01-30 | — | — | US | disclosed |
| EP-1263471-A2 | ANTIMICROBIAL COMPOUNDS AND FORMULATIONS | ALPHARMA AS (NO) | 2002-12-11 | — | — | EP | disclosed |
| WO-2001066147-A2 | ANTIMICROBIAL COMPOUNDS AND FORMULATIONS | ALPHARMA AS (NO) | 2001-09-13 | — | — | WO | disclosed |
| EP-1109831-A2 | CYCTOTOXIC PEPTIDES MODIFIED BY BULKY OR LIPOPHILIC MOIETIES | ALPHARMA AS (NO) | 2001-06-27 | — | — | EP | disclosed |
| EP-1109827-A2 | BIOACTIVE PEPTIDES | ALPHARMA AS (NO) | 2001-06-27 | — | — | EP | disclosed |
| WO-2000012542-A2 | CYTOTOXIC LACTOFERRIN DERIVATIVES MODIFIED BY BULKY OR LIPOPHILIC MOIETIES | ALPHARMA AS (NO) | 2000-03-09 | — | — | WO | disclosed |
| WO-2000012541-A2 | CYTOTOXIC PEPTIDES MODIFIED BY BULKY OR LIPOPHILIC MOIETIES | ALPHARMA AS (NO) | 2000-03-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030148936-A1 | Bioactive peptides | VIP, NGLY1, HM13 | MDM2 1236/4885MDM4 2081/4885TP53 15/4885 |
| US-20030195144-A1 | Antimicrobial compounds and formulations | LPO, CLPTM1, VIP | MDM2 3983/4885MDM4 3015/4885TP53 3368/4885 |
| US-20030022821-A1 | Bioactive peptides | VIP, LITAF, LNPEP | MDM2 1860/4885MDM4 1156/4885TP53 91/4885 |
| US-20120251459-A1 | SPECIFIC INHIBITORS AND ACTIVE SITE PROBES FOR LEGUMAIN | ENGASE, LGMN, DNPEP | MDM2 593/4885MDM4 3624/4885TP53 1981/4885 |
| US-20140037657-A1 | INHIBITION OF TUMOR GROWTH | STING1, VIP, MIF | MDM2 614/4885MDM4 314/4885TP53 12/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.